test

Head and Neck Cancer

10
(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lip, Oral Cavity and Pharynx | Stomach
Principal Investigator: Lajos Pusztai
A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (ECOG E1305)
Disease/Condition: Head and Neck Cancer | Larynx | Lip, Oral Cavity and Pharynx
Principal Investigator: Hari Deshpande
A Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (RTOG 1216)
Principal Investigator: Roy Decker
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-Radiotherapy in Primary Unresected Patients with Stage III, IVa, or IVb Loco-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Disease/Condition: Brain and Nervous System | Other Respiratory and Intrathoracic Organs
Principal Investigator: Anne Chiang